Bio-link Australia Pty. Ltd.

News

Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

Christos Papadimitriou & Lilly Bojarski selected for 2018 Bridge Program

Bio-Link’s Christos Papadimitriou and Lilly Bojarski have been selected for the MTPCOnnect Bridge Program 2018, which offers strategic professional training to advance skills necessary to boost the commercialisation of Australian innovative research and biotechnologies. Bio-Link is pleased to be represented for a second year, following the inauguration of the initiative in 2017. Learn more about the program here.

4th January 2018 – Bio-Link Engaged by FivepHusion

Bio-Link has been engaged by FivepHusion Pty Ltd to assist with commercialisation of Deflexifol.  FivepHusion has developed Deflexifol, an innovative formulation of 5-FU and leucovorin, as a replacement for the current standard of care in solid tumour indications. A Phase II clinical in colorectal carcinoma trial is planned. To learn more about this opportunity, please click here.

19th October 2017 – Heptares Therapeutics engages Bio-Link to identify clinical collaborators

Heptares Therapeutics, a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs) has engaged Bio-Link to identify clinical collaborators for clinical studies investigating the role of individual GPCRs in human health and there role in human pathogenesis.

17th July 2017 – Bio-Link’s Dr Lieven Huang Attending ‘Business of Regenerative Medicine’ in Toronto This Week

After winning a CCRM Australia grant, Bio-Link’s Dr Lieven Huang is attending the 2017 edition of ‘Business of Regenerative Medicine’ in Toronto, which is focused on the latest in commercialising regenerative medicine and stem cell therapies. The event is co-hosted by the Centre for Commercialization of Regenerative Medicine (CCRM) and the Rotman School of Management. More information about the event here.

10th July 2017 – First Dosing in a Phase 1b Combination Trial of the Dynamin Inhibitor Prochlorperazine and Anti-EGFR Monoclonal Antibody Cetuximab in Head and Neck Squamous Cell Carcinoma Patients.

The first two patients have been dosed in a phase Ib clinical trial at the Princess Alexandra Hospital (PAH, Brisbane, Australia), evaluating the efficacy of co-treatment of the anti-psychotic / anti-emetic drug prochlorperazine (Stemetil®) with anti-EGFR monoclonal antibody (mAb) cetuximab in head and neck squamous cell carcinoma (HNSCC) patients (HREC/16/QPAH/825). Prochlorperazine is a potent off-target inhibitor of the enzyme dynamin II. To learn more, please click here.